Clinical economic analysis of using eribulin (halaven) for treatment of patients with metastatic breast cancer

Breast cancer is the most common cause of death from cancer among women in Russia. More than half of patients have metastases at diagnosis. Chemotherapy is an important component of combined modality treatment for breast cancer. The budget impact analysis of expenses for the use of eribulina demonstrated that its inclusion in the «List of Essential Drugs» greatly expand the possibilities of treatment for metastatic breast cancer without causing significant additional burden on the health budget of the Russian Federation.